Comparison of Response Duration with that of last Chemotherapy Regimen

A planned secondary analysis was conducted comparing the duration of response to C2B8 with the duration of response to the most recent chemotherapy regimen. The overall response rate to C2B8 was lower than the response rate to most recent chemotherapy regimen [50% ORR to C2B8 vs. 73% (117/161) to last chemotherapy]. A comparison of the overall and complete response rates and the duration of response to C2B8 vs. the response rates and duration of response to most recent chemotherapy regimen was conducted in the subset of 80 patients who had responded to C2B8. The overall and complete response rates and the response duration to the most recent chemotherapy regimen were higher. The majority of patients who responded to C2B8 had responded to the most recent chemotherapy regimen (81%), and approximately half (41/78) had had a complete response to the most recent chemotherapy regimen.

COMPARISON OF C2B8 RESPONSE RATE AND DURATION TO MOST RECENT CHEMOTHERAPY					
Population	Overall response rate	Complete response rate	Response duration		
C2B8 responders: Response to C2B8 (n=78)	78/161 (48%)	lo/161 (6%)	9.2 + months		
C2B8 responders: Response to prior chemotherapy (n=78)	63/78 (81%)	41/78 (53%)	20.0 months		
All patients with response to last chemotherapy (n=117)	117/161 (73%)	60/161 (37%)	12.0 months		

The next table provides the results of overall and complete response rates and response duration to C2B8, according to the number of prior chemotherapeutic regimens. Of note, neither the overall nor complete response rate decreased with an increasing number of prior chemotherapeutic regimens. The response duration data are not mature enough to make an assessment on whether the duration of response to C2B8 varies according to extent of prior therapy.

DURATION OF RESPONSE, BASED ON THE NUMBER OF PREVIOUS CHEMOTHERAPEUTIC COURSES				
Prior Chemotx Courses	ORR	CR	Median Duration of Response (months)	
0	40% (2/5)	0%	8.6+	
1	59% (30/51)	8% (4/51)	9.1+	
2	31% (11/36)	6% (2/36)	9.8+	
3	49% (24/49)	4% (2/49)	8.1+	
≥4	52% (13/25)	8% (2/25)	9.2+	
All	48% (80/166)	6% (10/166)	9.2+	